SLC35A3 Human Pre-designed siRNA Set A

Cat. No.: S1489313

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

SLC35A3 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC35A3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components SLC35A3 siRNA-1: 5 nmol (HPLC) SLC35A3 siRNA-2: 5 nmol (HPLC) SLC35A3 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Product Line

Prodotti biologici

Application Protocols

• Item-specific tested applications, recommended dilutions, or validated cell lines: Not specified for this item; refer to CoA/Spec Sheet.

• Notes

  • As a general reference only, protocol concepts for siRNA delivery and knockdown optimization are provided under the “Reaction Conditions” tab. Follow your institution’s SOPs and the instructions for your chosen transfection reagent.
  • This product is for research use only.

Biological Roles

• Target overview (literature; not item-specific claims)

  • SLC35A3 encodes a Golgi-resident nucleotide sugar transporter, primarily mediating the import of UDP-N-acetylglucosamine (UDP-GlcNAc) from cytosol into the Golgi lumen. It belongs to the solute carrier family 35 (nucleotide sugar transporters).
  • Biological processes: N-linked and O-linked glycosylation pathways, proteoglycan biosynthesis, and broader glycome homeostasis. Proper UDP-GlcNAc transport supports glycosyltransferase reactions in the secretory pathway.

• Functional implications of knockdown (general research context)

  • Reducing SLC35A3 expression is expected to dampen Golgi UDP-GlcNAc availability, potentially altering N-glycan branching and glycoprotein maturation. Phenotypic readouts may include shifts in lectin-binding profiles (e.g., L-PHA/E-PHA), changes in secreted protein glycoforms, and ER/Golgi stress markers.
  • Systems-level effects may manifest in trafficking efficiency, receptor stability at the plasma membrane, and signaling pathways sensitive to glycosylation status.

• Experimental considerations

  • Use lectin blotting/flow cytometry and glycomics to quantify glycosylation alterations. Pair mRNA quantitation (RT-qPCR) with proteomic assessment of glycoproteins to confirm pathway-level impact.
  • Rescue experiments (co-transfection with siRNA-resistant cDNA) strengthen specificity conclusions (general best practice).

• Note on this item

  • This product is for research use only. No clinical/diagnostic applications are claimed or supported.

Buffer Applications

• Applicability

  • This product is an siRNA; classical biochemical buffer systems (e.g., Good’s buffers) as buffering agents are not its purpose. Instead, buffers are used to dissolve, store, and deliver the siRNA.

• General guidance (not item-specific)

  • Stock preparation: RNase-free water or low-ionic-strength TE (10 mM Tris-HCl, 0.1–1 mM EDTA, pH 7.5–8.0) are commonly used to enhance stability.
  • Working solutions: for lipid-mediated transfection, complex siRNA in serum-free media optimized for transfection (e.g., Opti-MEM) before adding to complete growth medium; verify compatibility with your reagent.
  • Avoid high concentrations of divalent cations (Mg2+, Ca2+) during complex formation as they can influence particle size and nuclease activity.

• Recipes/specifications

  • Specific buffer composition and recommended concentrations for this item: Not specified for this item; refer to CoA/Spec Sheet.

• Practical notes

  • Maintain nuclease-free technique at all times. Do not subject siRNA solutions to vigorous vortexing or repeated passage through small-bore tips to minimize shear and adsorption losses.

Green Alternatives

• Context

  • siRNA workflows are inherently aqueous and can be aligned with green chemistry/biology principles by minimizing hazardous reagents, plastic waste, and energy usage.

• Greener choices (general guidance)

  • Transfection reagents: prefer lipid formulations with documented low cytotoxicity and serum compatibility to reduce repeats and waste from failed transfections.
  • Buffers/solvents: use RNase-free water and minimal-salt buffers; avoid DEPC-treated solutions where unnecessary to reduce hazardous handling (choose certified nuclease-free reagents instead).
  • Energy and cold chain: consolidate freezer space and employ -20 °C (as specified for this item) rather than -80 °C when stability permits; aliquot to minimize repeated freeze–thaw.
  • Waste reduction: plan pooled siRNA screens to decrease the number of separate transfections; use multiwell plates optimized for lower volumes to reduce reagent consumption.
  • Reusable equipment: prefer RNase-decontaminable, reusable racks and minimize single-use plastics where contamination risk is controlled.

• Comparative considerations

  • For hard-to-transfect cells, electroporation can eliminate cationic lipids but may increase energy use and cell stress; modern low-toxicity lipids in serum can be a greener, gentler alternative.

• Note on this item

  • No hazardous stabilizers or solvent systems are specified in the Product Data for this siRNA; consult the CoA/Spec Sheet for any formulation details before implementing green substitutions.

Pharmaceutical Uses

• Applicability

  • This is a research-use-only siRNA product. It is not intended for human or veterinary use, diagnostics, or as a therapeutic or excipient.

• General industry context (literature; not item-specific)

  • In pharmaceutical research, RUO siRNAs are frequently used for target validation, pathway mapping, and mechanism-of-action studies that inform early discovery decisions.
  • Process considerations for translational/developmental settings (outside the scope of this RUO product) may include GMP manufacturing, defined impurity profiles, endotoxin control, and specialized formulations (e.g., LNPs). None of these are specified for this item.

• Regulatory/status statements

  • Pharmacopeial monographs do not generally cover gene-specific siRNA reagents. Use under appropriate institutional approvals for in vitro research only.

• Item-specific note

  • Any claims of compliance (GMP, pharmacopoeia) or formulation suitability: Not specified for this item; refer to CoA/Spec Sheet if available.

Physical Properties

• Item-specific specifications

  • Molecular weight, strand length, extinction coefficient, and concentration per vial: Not specified for this item; refer to CoA/Spec Sheet.
  • Appearance: Not specified for this item; siRNA is commonly supplied lyophilized or in aqueous buffer (general).

• Literature/general (typical for siRNA; not item-specific)

  • Physical state: lyophilized solid or frozen aqueous solution; hygroscopic; readily water-soluble under RNase-free conditions.
  • Solubility: freely soluble in RNase-free water and common biological buffers (e.g., TE, PBS variants without Mg2+/Ca2+ when preparing stocks for transfection); insoluble in organic solvents.
  • Approximate molecular mass: depends on length and modifications; a 21-mer duplex typically totals ~13–15 kDa (two ~6–7.5 kDa strands).
  • UV properties: strong absorbance at ~260 nm; A260 to concentration conversion requires strand-specific extinction coefficients computed from sequence (nearest-neighbor model).
  • Thermal behavior: duplex melting temperature (Tm) depends on GC content, length, salt, and modifications; antisense activity occurs in RISC at 37 °C in cells; no discrete “boiling point/melting point” in classical small-molecule sense.
  • pH stability: RNA backbones are base-labile; avoid alkaline conditions (≥pH 9). Acidic conditions can promote depurination at extremes—neutral pH buffers are preferred.

• Practical implications

  • Prepare and store in RNase-free, nuclease-free aqueous solutions; avoid divalent cations unless protocol requires (can promote nuclease activity).

Quality and Grades

• Item-specific status

  • Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.
  • Composition (sequences, modifications), OD units/mass, and purification method: Not specified for this item; refer to CoA/Spec Sheet.

• General context for siRNA quality (literature/industry practice)

  • Common purification levels: desalted (basic desalting), cartridge/OPC, PAGE, or HPLC. For cell-based knockdown, HPLC- or PAGE-purified strands are often preferred to reduce truncated species.
  • Typical QC tests: UPLC/HPLC purity, MS confirmation of each strand, UV A260 assay for quantitation, endotoxin/bioburden (for sensitive cell systems), duplex annealing verification, and residual salt/solvent testing.
  • Stabilizers/additives: some products include RNase-free buffers or lyoprotectants (e.g., trehalose) to enhance stability; if present, they will be listed on the CoA/Spec Sheet (not specified here).

• What “pre-designed set” implies

  • A set usually contains 2–4 distinct siRNA duplexes targeting different regions of SLC35A3 to mitigate off-targets and sequence-specific variability, facilitating selection of the most effective duplex in your system.

• Recommendations

  • For quantitative work, verify strand concentration by A260 using sequence-specific extinction coefficients (from CoA or vendor calculator).
  • For sensitive applications (primary cells, iPSCs), check specifications for purity level and endotoxin; absence of such data here means you should consult the CoA/Spec Sheet for confirmation.

Reaction and Applications

• Scope of use

  • Designed for RNA interference (RNAi)-mediated, transient knockdown of human SLC35A3 expression in cultured cells for pathway dissection, target validation, and phenotypic screening (in vitro research use).

• Experimental design (literature/general guidance; not item-specific)

  • Use multiple duplexes from the pre-designed set to identify the most effective sequence; combine top performers or pool at reduced individual concentrations to minimize off-target effects.
  • Include controls: non-targeting siRNA, positive knockdown control (e.g., PLK1 in proliferating cells), and mock transfection.
  • Typical working concentrations: 1–50 nM final siRNA, depending on cell type and delivery method. Start with a titration (e.g., 1, 5, 10, 25 nM).
  • Delivery methods: lipid-mediated transfection (forward or reverse), electroporation for hard-to-transfect cells, or polymer-based systems. Optimize cell density and reagent ratios.

• Readouts and timelines

  • mRNA reduction is often measurable by RT-qPCR at 24–48 h; protein depletion by immunoblot or proteomics at 48–96 h, depending on protein half-life.

• Troubleshooting tips

  • Low knockdown: verify transfection efficiency (fluorescent control), increase siRNA or reagent slightly, or switch delivery method; ensure RNA integrity by A260/280 and gel/CE.
  • Toxicity: reduce reagent/siRNA amounts, shorten complexation time, change serum conditions, or use more biocompatible lipids.

• Note on this item

  • Specific sequences and any chemical modifications: Not specified for this item; refer to CoA/Spec Sheet.

Reaction Conditions

• Applicability

  • For siRNA, “reaction conditions” correspond to transfection and knockdown conditions in cell culture. The following are literature-based general guidelines and are not item-specific.

• Typical transfection conditions (general)

  • Cell density: 40–70% confluence at transfection to balance uptake and viability.
  • siRNA dose: 1–50 nM final; begin with a titration (e.g., 1, 5, 10, 25 nM).
  • Complexation: mix siRNA with lipid reagent in serum-free medium (e.g., Opti-MEM) and incubate 5–20 min at room temperature to allow complex formation; follow reagent instructions.
  • Incubation: add complexes to cells; after 4–6 h, optionally replace with complete medium if required by reagent. Maintain at 37 °C, 5% CO2.
  • Assessment: assay mRNA at 24–48 h; protein at 48–96 h. Extend to 5–7 days for long-lived proteins or perform repeat dosing.

• Controls and validation

  • Include non-targeting control, positive control siRNA, and mock transfection. Verify transfection efficiency (fluorescent oligo or labeled control). Confirm on-target effects via qPCR and orthogonal readouts (e.g., glycosylation-sensitive lectin assays for SLC35A3-related pathways).

• Notes on this item

  • Specific recommended reagent, dose, and sequences: Not specified for this item; refer to CoA/Spec Sheet and optimize empirically for your cell model.

Safety and Handling

• Product Data

  • Storage: Store at -20°C.
  • Shipping: Ice chest + ice pads.
  • GHS classification, signal word, pictograms, H-statements: Not specified for this item; refer to SDS.

• General laboratory safety (literature/best practice; not item-specific)

  • siRNA oligonucleotides are generally considered low hazard; handle using standard laboratory PPE: lab coat, nitrile gloves, and safety glasses.
  • Maintain RNase-free technique: use dedicated RNase-free tips/tubes, wear clean gloves, and avoid contact with skin/hair and common RNase sources. Clean work surfaces and equipment with RNase-decontamination solutions.
  • Avoid aerosol generation when opening lyophilized vials. Reconstitute gently to prevent foaming and shearing.
  • Incompatibilities: avoid strong bases (RNA is base-labile), avoid nucleases (RNase A and environmental RNases), and minimize exposure to elevated temperatures and UV light which can degrade RNA.

• First-aid overview (consult SDS for authoritative guidance)

  • Inhalation/ingestion/skin/eye exposure: rinse affected area with water; seek medical attention if irritation persists. Provide SDS to healthcare personnel.

• Waste disposal

  • Dispose of unused material/solutions according to institutional guidelines for non-hazardous biological/chemical waste; decontaminate surfaces/tools for RNases as per facility SOPs.

• Emergency considerations

  • Product is non-volatile and non-flammable; primary risks are loss of activity via RNase contamination or thermal degradation rather than acute chemical hazards.

Solvent Selection

• Applicability

  • As an RNA oligonucleotide duplex, dissolution is in aqueous, RNase-free media rather than organic solvents.

• Recommended solvents and rationale (general guidance)

  • RNase-free water: default for stock solutions; minimizes ionic strength and avoids nuclease cofactors.
  • TE buffer (10 mM Tris-HCl, 0.1–1 mM EDTA, pH 7.5–8.0): enhances stability during long-term storage by chelating divalent cations that can catalyze degradation; ensure compatibility with your transfection reagent (some lipids prefer salt-free conditions for complex formation).
  • PBS (without Ca2+/Mg2+): acceptable for dilutions/handling steps; not ideal for complex formation with certain cationic lipids due to ionic strength.

• Not recommended

  • Organic solvents (e.g., ethanol, DMSO, DMF) are not used for siRNA dissolution and can impair transfection complex formation or cell viability.

• Practical tips

  • Prepare concentrated stocks (e.g., 10–100 µM) in RNase-free water, then dilute into serum-free Opti-MEM or equivalent for complexation with lipid reagents (verify with your reagent’s datasheet). Label as general guidance; verify conditions empirically.
  • Filter sterilization is usually unnecessary when using nuclease-free reagents; avoid 0.22 µm filtration which can adsorb oligos.

• Note on this item

  • Specific solvent, buffer composition, and recommended stock concentration: Not specified for this item; refer to CoA/Spec Sheet.

Storage and Reconstitution

• Item-specific instructions (Product Data)

  • Storage: Store at -20°C.
  • Shipping: Ice chest + ice pads.

• Not specified for this item; refer to CoA/Spec Sheet

  • Exact form (lyophilized vs. solution), reconstitution volume, recommended stock concentration, buffer composition, and any stabilizers/cryoprotectants.

• General guidance (best practice; not item-specific)

  • Handle under RNase-free conditions. If lyophilized, briefly centrifuge before opening to collect contents at the bottom of the vial.
  • Reconstitute with nuclease-free water (or TE buffer if compatible with downstream use) to a convenient stock concentration. Mix gently by pipetting; avoid vigorous vortexing.
  • Aliquot immediately to avoid repeated freeze–thaw cycles. Store working aliquots at -20°C (short-to-mid term) and minimize freeze–thaw; keep on ice during use.
  • For long-term storage stability, some labs keep siRNA at -80°C; however, this item specifies -20°C. Follow the Product Data/CoA, and validate stability in your workflow.
  • Thaw on ice, briefly spin down condensate, and keep solutions cold during setup. Avoid prolonged exposure to ambient temperatures and direct light.

• Documentation

  • Record reconstitution date, solvent/buffer, concentration, and number of freeze–thaw events to support reproducibility and QC.

Structure and Identity

• Item-specific facts (Product Data)

  • Product: SLC35A3 Human Pre-designed siRNA Set A (SKU: S1489313)
  • Intended target: human SLC35A3 mRNA (gene symbol SLC35A3; solute carrier family 35 member A3)
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • CAS, CID, InChIKey, SMILES: Not specified for this item; siRNA duplexes typically lack standard SMILES/InChI representations used for small molecules.

• Literature/general description (not item-specific)

  • siRNA is a short double-stranded RNA duplex, commonly 19–21 bp with 2-nt 3′ overhangs (e.g., dTdT), bearing 5′-phosphate/3′-hydroxyl termini unless chemically modified.
  • Structural features: ribose sugar (2′-OH), phosphodiester (or modified) backbone, canonical A-form helical geometry; optional stabilizing modifications (e.g., 2′-O-Me, 2′-F, phosphorothioate) may be used depending on design.
  • 2D depiction would show two antiparallel RNA strands (sense/antisense) base-paired via Watson–Crick pairing, with potential short 3′ overhangs.

• Notes on identity and traceability

  • This is a “pre-designed set,” typically comprising multiple non-overlapping siRNA duplexes against SLC35A3 to improve knockdown robustness; exact sequences/lengths are not provided here. Consult the CoA/Spec Sheet for strand sequences, modification patterns (if any), and OD/mass per vial.
  • Sequence-level identity verification in practice uses MALDI-TOF/ESI-MS of component strands and/or capillary electrophoresis/HPLC profiles (literature/general).

Synthetic Utility

• Applicability

  • Not a small-molecule building block or synthetic reagent; therefore, classical organic synthesis utility (e.g., as a coupling partner, catalyst, or solvent) does not apply.

• Relevant laboratory utility (general research perspective)

  • Serves as a genetic perturbation tool enabling functional genomics experiments, epistasis testing, and pathway deconvolution through transient knockdown of SLC35A3.
  • Can be used to benchmark CRISPRi or ASO designs by comparing knockdown efficacy and phenotypic outcomes.

• Item-specific constraints

  • Any covalent modifications enabling conjugation/chemistry (amine, thiol, azide handles) are not described here. Specific strand sequences or modification handles: Not specified for this item; refer to CoA/Spec Sheet.

Target Specificity

• Item-specific facts (from Product Name)

  • Intended target: human SLC35A3 mRNA (solute carrier family 35 member A3).
  • Product type: Pre-designed siRNA Set A (multiple siRNA duplexes typically provided to enhance likelihood of effective knockdown).
  • Exact sequences, target exons/regions, and any chemical modifications: Not specified for this item; refer to CoA/Spec Sheet.

• General considerations (literature; not item-specific)

  • Specificity of siRNA derives from perfect (or near-perfect) complementarity of the antisense strand to the target mRNA. Off-target effects can arise from seed-region matches (positions 2–8) to unintended transcripts.
  • Mitigation strategies include using pools of low-dose siRNAs, conducting mismatch controls, and performing rescue experiments with siRNA-resistant cDNA.

• Not an antibody product

  • Fields such as clone, isotype, epitope mapping, or species cross-reactivity do not apply to siRNA reagents.